(RVTY) Revvity - Ratings and Ratios

Revvity Inc., formerly known as PerkinElmer, Inc., is a global provider of health sciences solutions, technologies, and services. The company operates through two main segments: Life Sciences and Diagnostics. Its Life Sciences segment offers a comprehensive range of products and services, including instruments, reagents, and software, that cater to the needs of pharmaceutical and biotechnology companies, laboratories, and research institutions. The Diagnostics segment provides innovative solutions for the early detection of genetic disorders, infectious diseases, and other medical conditions.

The companys product portfolio is diverse, with a range of brands that serve various markets, including oncology, newborn screening, and immunodiagnostics. Revvitys technologies enable and support genomic workflows, including next-generation DNA sequencing, and are used by healthcare professionals, researchers, and government agencies worldwide. With a history dating back to 1937, Revvity has established itself as a leader in the life sciences and diagnostics industries.

Analyzing the technical data, we can see that RVTYs stock price is currently at $90.50, with a 20-day SMA of $92.04 and a 50-day SMA of $94.76, indicating a downward trend. The 200-day SMA is at $111.91, suggesting that the stock has been trending downwards over the long term. The ATR is 3.13, which translates to a volatility of 3.46%. The 52-week high and low are $127.50 and $89.32, respectively. Based on this data, we can forecast that the stock may continue to experience a downward trend in the short term, with potential support at the 52-week low.

From a fundamental perspective, Revvitys market capitalization is approximately $10.53 billion, with a P/E ratio of 36.91 and a forward P/E of 18.15. The companys return on equity is 3.69%. Using this data, we can forecast that the companys earnings growth may be a key driver of the stocks performance. If Revvity can deliver on its growth prospects, the stock may experience a rebound. However, if the companys earnings disappoint, the stock may continue to underperform. Based on the technical and fundamental data, our forecast is that RVTY may trade in a range between $85 and $100 in the short term, with a potential breakout above $100 if the companys earnings growth meets expectations.